牛牛AI助手已提取核心信息银诺医药2025年上半年实现收入人民币5644.6万元,主要来自依苏帕格鲁肽α在中国的商业化销售。期内毛利为5049万元,毛利率89.4%。受研发投入增加及商业化团队扩张影响,期内亏损同比扩大62.7%至1.22亿元,研发开支增长90.9%至9908.2万元。公司于2025年1月获得依苏帕格鲁肽α用于治疗2型糖尿病的监管批准,并于2月在中国实现商业化。同年6月在澳门获得...
Source Link牛牛AI助手已提取核心信息银诺医药2025年上半年实现收入人民币5644.6万元,主要来自依苏帕格鲁肽α在中国的商业化销售。期内毛利为5049万元,毛利率89.4%。受研发投入增加及商业化团队扩张影响,期内亏损同比扩大62.7%至1.22亿元,研发开支增长90.9%至9908.2万元。公司于2025年1月获得依苏帕格鲁肽α用于治疗2型糖尿病的监管批准,并于2月在中国实现商业化。同年6月在澳门获得...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.